Immune-related adverse events after 2 years in patients with advanced non-small-cell lung cancer receiving extended immune checkpoint inhibitor therapy.

被引：0
|
作者：
Elghawy, Omar
Barsouk, Adam
Sussman, Jonathan Henry
Davella, Christopher
Singh, Aditi Puri
Ciunci, Christine Agnes
Robinson, Kyle William
Kosteva, John A.
Langer, Corey J.
Cohen, Roger B.
Aggarwal, Charu
Marmarelis, Melina Elpi
Sun, Lova
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Univ Penn, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients
    Kashiwabara, Kosuke
    Fujii, Shinji
    Tsumura, Shinsuke
    Sakamoto, Kazuhiko
    ANTI-CANCER DRUGS, 2020, 31 (08) : 872 - 875
  • [2] Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
    Naidoo, Jarushka
    Johnson, Douglas B.
    Doran, Charlotte
    Wang, Yuexi
    Zhang, Yan
    Le, Trong Kim
    Hopson, Sari
    Dreyfus, Brian
    Lal, Lincy S.
    Vyas, Charmy
    Goldstein, Shay
    Izadi, Zara
    ONCOLOGIST, 2024,
  • [3] Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer
    Grangeon, Mathieu
    Tomasini, Pascale
    Chaleat, Solene
    Jeanson, Arnaud
    Souquet-Bressand, Maxime
    Khobta, Nataliya
    Bermudez, Julien
    Trigui, Youssef
    Greillier, Laurent
    Blanchon, Marilyne
    Boucekine, Mohamed
    Mascaux, Celine
    Barlesi, Fabrice
    CLINICAL LUNG CANCER, 2019, 20 (03) : 201 - 207
  • [4] Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
    Biniakewitz, Matthew D.
    Kasler, Mary Kate
    Fessele, Kristen L.
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2021, 8 (01) : 18 - 24
  • [5] Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
    Inoue, Yusuke
    Inui, Naoki
    INTERNAL MEDICINE, 2024,
  • [6] Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
    Dolladille, Charles
    Ederhy, Stephane
    Sassier, Marion
    Cautela, Jennifer
    Thuny, Franck
    Cohen, Ariel A.
    Fedrizzi, Sophie
    Chretien, Basile
    Da-Silva, Angelique
    Plane, Anne-Flore
    Legallois, Damien
    Milliez, Paul U.
    Lelong-Boulouard, Veronique
    Alexandre, Joachim
    JAMA ONCOLOGY, 2020, 6 (06) : 865 - 871
  • [7] CARDIAC IMMUNE-RELATED ADVERSE EVENTS IN LUNG CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS
    Kumar, Sany
    Fowler, Cosmo
    Thota, Ajit K.
    Pastores, Stephen M.
    CHEST, 2023, 164 (04) : 363A - 363A
  • [8] Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
    Daniello, Lea
    Elshiaty, Mariam
    Bozorgmehr, Farastuk
    Kuon, Jonas
    Kazdal, Daniel
    Schindler, Hannah
    Shah, Rajiv
    Volckmar, Anna-Lena
    Lusky, Fabienne
    Diekmann, Leonore
    Liersch, Stephan
    Faehling, Martin
    Muley, Thomas
    Kriegsmann, Mark
    Benesova, Karolina
    Stenzinger, Albrecht
    Thomas, Michael
    Christopoulos, Petros
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Implementation and impact of a novel multidisciplinary immune-related adverse events tumor board for patients receiving immune checkpoint inhibitor therapy.
    Boruah, Abhilasha Pankaj
    Demski, Kathryn
    Patil, Pradnya Dinkar
    Calabrese, Cassandra
    Funchain, Pauline
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
    Conde-Estevez, David
    Monge-Escartin, Ines
    Rios-Hoyo, Alejandro
    Monzonis, Xavier
    Echeverria-Esnal, Daniel
    Moliner, Laura
    Duran-jorda, Xavier
    Taus, Alvaro
    Arriola, Edurne
    JOURNAL OF CHEMOTHERAPY, 2020, 33 (01) : 32 - 39
12345